We search for integrated genomic blueprints that enable us to predict how cancer will evolve and respond to treatment.
Francesca Buffa is an Associate Professor in the Department of Oncology, University of Oxford, where she leads the Computational Biology and Integrative Genomics Group.
After a Masters Degree in Theoretical Physics from the University of Turin, Prof Buffa completed her PhD in Physics and Mathematical Modelling at the Institute of Cancer Research within the University of London. She then undertook a postdoctoral research fellowship in Mathematical Modelling and Biostatistics at the Gray Cancer Institute, London before joining the Molecular Oncology Laboratories at the Weatherall institute of Molecular Medicine, University of Oxford, first as a postdoctoral research fellow in Bioinformatics/Biostatistics then as a Group Leader.
Prof Buffa took up her current post in the Department of Oncology in 2013 where she leads a research team working at the interface between computational biology, genomics and biomarker research. In addition to her research programme, she teaches at national and international Masters Courses and Advanced Schools, and acts as bioinformatics/biostatistics advisor for genomics clinical research studies and trials. She has been invited to present her work at national and international conferences, and authored or co-authored over 100 publications, several in high impact journals.
Syed Haider, Alan McIntyre, Ruud G. P. M. van Stiphout, Laura M. Winchester, Simon Wigfield, Adrian L. Harris and Francesca M. Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology (2016) 17:140 http://rdcu.be/tMm
Masiero M, Costa Simões F, Dong Han H, Snell C, Peterkin T, Bridges E, Mangala LS, Yen-Yao Wu S, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL and Buffa FM. A core human primary tumor angiogenesis signature identifies the endothelial orphan eceptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12;24(2):229-41. doi: 10.1016/j.ccr.2013.06.004. Epub 2013 Jul 18.
Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, Steers G, Turley H, Li JL, Günther UL, Buffa FM, McIntyre A and Harris AL. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 2012 Dec 5;16(6):751-64. doi: 10.1016/j.cmet.2012.10.017. Epub 2012 Nov 21.
Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst Monogr. 2011;2011(43):71-4. doi: 10.1093/jncimonographs/lgr027.
Google scholar: https://scholar.google.co.uk/citations?user=abd1LXcAAAAJ&hl=en&oi=ao
Research gate: https://www.researchgate.net/profile/Francesca_Buffa
Alessandro Barberis, Postdoctoral Researcher
Jagat Chauhan, Postdoctoral Researcher (in collaboration with Oxford Ludwig Institute)
Wei-Chen Cheng, Postdoctoral Researcher
Pauline Robbe, DPhil Student
Dimitrios Voukantsis, Postdoctoral Researcher